Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

THOMAS J GEORGE

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1104867365
CMS profile
321938
Location
GAINESVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$2,260.64

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $2,100.00 1
Food and Beverage $117.39 1
Education $43.25 1

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
PFIZER INC. $2,100.00 1
Regeneron Pharmaceuticals, Inc. $117.39 1
AstraZeneca Pharmaceuticals LP $43.25 1

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

THOMAS J GEORGE

NPI 1104867365 · CMS profile ID 321938

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

GAINESVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1104867365?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
THOMAS J GEORGE, NPI 1104867365, CMS profile ID 321938. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1104867365?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). THOMAS J GEORGE, NPI 1104867365, CMS profile ID 321938. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1104867365?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
THOMAS J GEORGE, NPI 1104867365, CMS profile ID 321938, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1104867365?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $2,260.64 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $43.2511/19/2025 Education No dispute reported Delay: No
Change: NEW
06/30/2026 1214773627 CMS
PFIZER INC. $2,100.0006/30/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1231728378 CMS
Regeneron Pharmaceuticals, Inc. $117.3901/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213238097 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,139.61 16
PY2020 $806.00 2
PY2021 $5,850.00 2
PY2022 $5,602.52 7
PY2023 $299.42 5
PY2024 $1,820.00 3
PY2025 $2,260.64 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $507,584.60 83
PY2024 Recipient $2,598.05 11
PY2024 Principal investigator $596,039.96 28
PY2023 Principal investigator $1,130,234.11 90
PY2022 Principal investigator $1,675,365.46 75
PY2021 Principal investigator $2,129,940.43 124
PY2020 Principal investigator $2,169,106.03 143
PY2019 Principal investigator $2,064,075.98 203

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

143 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,459.65 12/31/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
MEDI9447 CD73 Solid Tmr-D6070C00001 Phase 1 Clinical Trial No dispute reported 06/30/2026 753915767
Principal investigator 1 Seagen Inc. $3,243.50 12/23/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 733447677
Principal investigator 1 Incyte Corporation $8,914.50 12/22/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303867
Principal investigator 1 Incyte Corporation $1,558.80 12/22/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303869
Principal investigator 1 Incyte Corporation $1,430.00 12/22/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303871
Principal investigator 1 Incyte Corporation $650.00 12/22/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303873
Principal investigator 1 Incyte Corporation $3,250.00 12/22/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303875
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $23,660.00 12/18/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma NEO-Nal- IRI Study No dispute reported 06/30/2026 740100485
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $23,660.00 12/10/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma NEO-Nal- IRI Study No dispute reported 06/30/2026 740100483
Principal investigator 1 Merck Sharp & Dohme Corporation $2,551.20 12/08/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation HRRm and,or Homologous Recombination Deficiency HRD Positive Advanced Cancer No dispute reported 06/30/2026 740781359
Principal investigator 1 Incyte Corporation $59.00 12/03/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 744303865
Principal investigator 1 Merck Sharp & Dohme Corporation $7,615.20 11/24/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation HRRm and,or Homologous Recombination Deficiency HRD Positive Advanced Cancer No dispute reported 06/30/2026 740781309
Principal investigator 1 GlaxoSmithKline, LLC. $112,511.40 11/17/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA DIVISION OF HEMATOLOGY & ONCOLOGY
214456 No dispute reported 06/30/2026 965523399
Principal investigator 1 Merck Sharp & Dohme Corporation $351.68 11/05/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation HRRm and,or Homologous Recombination Deficiency HRD Positive Advanced Cancer No dispute reported 06/30/2026 740781397
Principal investigator 1 Seagen Inc. $3,008.20 11/03/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 733447675
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $23,660.00 10/16/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma NEO-Nal- IRI Study No dispute reported 06/30/2026 740100481
Principal investigator 1 Merck Sharp & Dohme Corporation $13,027.98 10/14/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation HRRm and,or Homologous Recombination Deficiency HRD Positive Advanced Cancer No dispute reported 06/30/2026 740781395
Principal investigator 1 Merck Sharp & Dohme Corporation $482.80 10/14/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation HRRm and,or Homologous Recombination Deficiency HRD Positive Advanced Cancer No dispute reported 06/30/2026 740781399
Principal investigator 1 Incyte Corporation $36,449.40 10/08/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303845
Principal investigator 1 Incyte Corporation $3,143.80 10/08/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303847
Principal investigator 1 Incyte Corporation $620.70 10/08/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303877
Principal investigator 1 Incyte Corporation $296.52 10/08/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303879
Principal investigator 1 Incyte Corporation $203.40 10/08/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303881
Principal investigator 1 Incyte Corporation $754.32 10/08/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303883
Principal investigator 1 Incyte Corporation $141.48 10/08/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303885
Principal investigator 1 Incyte Corporation $14.04 10/08/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303887
Principal investigator 1 Incyte Corporation $30.40 10/08/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303889
Principal investigator 1 Incyte Corporation $140.64 10/08/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303891
Principal investigator 1 Seagen Inc. $520.00 10/07/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 733447671
Principal investigator 1 Seagen Inc. $780.00 10/07/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 733447673
Principal investigator 1 Incyte Corporation $256.00 09/17/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome No dispute reported 06/30/2026 744303827
Principal investigator 1 GlaxoSmithKline, LLC. $112,511.40 09/10/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA DIVISION OF HEMATOLOGY & ONCOLOGY
214456 No dispute reported 06/30/2026 965523395
Principal investigator 1 Merck Sharp & Dohme Corporation $5,904.00 09/08/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation HRRm and,or Homologous Recombination Deficiency HRD Positive Advanced Cancer No dispute reported 06/30/2026 740781273
Principal investigator 1 Merck Sharp & Dohme Corporation $13,027.98 09/08/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation HRRm and,or Homologous Recombination Deficiency HRD Positive Advanced Cancer No dispute reported 06/30/2026 740781353
Principal investigator 1 Incyte Corporation $4,480.00 08/27/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 744303807
Principal investigator 1 Incyte Corporation $1,536.00 08/27/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 744303809
Principal investigator 1 Incyte Corporation $704.00 08/27/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 744303811
Principal investigator 1 Incyte Corporation $576.00 08/27/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 744303813
Principal investigator 1 Incyte Corporation $2,100.00 08/27/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 744303815
Principal investigator 1 Incyte Corporation $2,058.00 08/27/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 744303817
Principal investigator 1 Incyte Corporation $1,536.00 08/27/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 744303819
Principal investigator 1 Merck Sharp & Dohme Corporation $1,300.00 08/27/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation HRRm and,or Homologous Recombination Deficiency HRD Positive Advanced Cancer No dispute reported 06/30/2026 740781307
Principal investigator 1 Merck Sharp & Dohme Corporation $1,405.60 08/21/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation HRRm and,or Homologous Recombination Deficiency HRD Positive Advanced Cancer No dispute reported 06/30/2026 740781271
Principal investigator 1 Seagen Inc. $520.00 08/19/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 733447623
Principal investigator 1 Merck Sharp & Dohme Corporation $26,055.96 08/06/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation HRRm and,or Homologous Recombination Deficiency HRD Positive Advanced Cancer No dispute reported 06/30/2026 740781361
Principal investigator 1 Seagen Inc. $18,782.40 08/04/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 733447625
Principal investigator 1 Incyte Corporation $4,968.00 07/30/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 744303797
Principal investigator 1 Amgen Inc. $1,994.13 07/28/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
AMG 510_P1/2 Monotherapy NSCLC/CRC/Tumor Agnostic_20170543 No dispute reported 06/30/2026 731622559
Principal investigator 1 Merck Sharp & Dohme Corporation $5,046.00 07/28/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation HRRm and,or Homologous Recombination Deficiency HRD Positive Advanced Cancer No dispute reported 06/30/2026 740781267
Principal investigator 1 Celgene Corporation $2,176.00 07/24/2020 Non-covered Recipient Entity
University Of Florida
Phase III Study - PANC-003 (BMS Study Number: CA139-P15) No dispute reported 06/30/2026 736444347
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $20,676.00 07/23/2020 Non-covered Recipient Entity
University of Florida Board of Trustees
A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma NEO-Nal- IRI Study No dispute reported 06/30/2026 740100245
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $3,000.00 07/16/2020 Non-covered Recipient Entity
University Of Florida
Clinical Study Site Agreement No dispute reported 06/30/2026 713688215
Principal investigator 1 Incyte Corporation $1.04 07/09/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303829
Principal investigator 1 Incyte Corporation $0.75 07/09/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303831
Principal investigator 1 Incyte Corporation $42.36 07/09/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303833
Principal investigator 1 Incyte Corporation $20.26 07/09/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303835
Principal investigator 1 Incyte Corporation $30.40 07/09/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303837
Principal investigator 1 Incyte Corporation $81.36 07/09/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303839
Principal investigator 1 Incyte Corporation $6.20 07/09/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303841
Principal investigator 1 Incyte Corporation $47.16 07/09/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303843
Principal investigator 1 Amgen Inc. $1,183.89 06/25/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
AMG 510_P1/2 Monotherapy NSCLC/CRC/Tumor Agnostic_20170543 No dispute reported 06/30/2026 731622563
Principal investigator 1 Seagen Inc. $6,357.00 06/24/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 733447571
Principal investigator 1 Merck Sharp & Dohme Corporation $579.36 06/22/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation HRRm and,or Homologous Recombination Deficiency HRD Positive Advanced Cancer No dispute reported 06/30/2026 740781391
Principal investigator 1 AstraZeneca Pharmaceuticals LP $39,533.31 06/18/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
MEDI9447 CD73 Solid Tmr-D6070C00001 Phase 1 Clinical Trial No dispute reported 06/30/2026 753915785
Principal investigator 1 GlaxoSmithKline, LLC. $90,009.12 06/18/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA DIVISION OF HEMATOLOGY & ONCOLOGY
214456 No dispute reported 06/30/2026 965523393
Principal investigator 1 Merck Sharp & Dohme Corporation $13,027.98 06/05/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation HRRm and,or Homologous Recombination Deficiency HRD Positive Advanced Cancer No dispute reported 06/30/2026 740781351
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $56,784.00 06/02/2020 Non-covered Recipient Entity
University of Florida Board of Trustees
A Phase II, Open-label Pilot Study Evaluating theSafetyandActivityof Liposomal Irinotecan in Combination With5-FUandOxaliplatinin Preoperative Treatment ofPancreatic AdenocarcinomaNEO-Nal- IRI Study No dispute reported 06/30/2026 740100571
Principal investigator 1 Merck Sharp & Dohme Corporation $289.68 06/02/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation HRRm and,or Homologous Recombination Deficiency HRD Positive Advanced Cancer No dispute reported 06/30/2026 740781355
Principal investigator 1 Incyte Corporation $15,534.90 05/28/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303789
Principal investigator 1 Incyte Corporation $6,600.60 05/28/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303791
Principal investigator 1 GlaxoSmithKline, LLC. $360,036.48 04/28/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA DIVISION OF HEMATOLOGY & ONCOLOGY
214456 No dispute reported 06/30/2026 965523397
Principal investigator 1 Merck Sharp & Dohme Corporation $2,390.65 04/28/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation HRRm and,or Homologous Recombination Deficiency HRD Positive Advanced Cancer No dispute reported 06/30/2026 740781269
Principal investigator 1 Merck Sharp & Dohme Corporation $527.52 04/24/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation HRRm and,or Homologous Recombination Deficiency HRD Positive Advanced Cancer No dispute reported 06/30/2026 740781357
Principal investigator 1 Seagen Inc. $2,558.40 04/22/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 733447567
Principal investigator 1 Seagen Inc. $3,705.00 04/22/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 733447569
Principal investigator 1 Seagen Inc. $14,690.00 04/22/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 733447573
Principal investigator 1 GlaxoSmithKline, LLC. $180,018.24 04/21/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA DIVISION OF HEMATOLOGY & ONCOLOGY
214456 No dispute reported 06/30/2026 965523401
Principal investigator 1 Merck Sharp & Dohme Corporation $13,027.98 04/20/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation HRRm and,or Homologous Recombination Deficiency HRD Positive Advanced Cancer No dispute reported 06/30/2026 740781317
Principal investigator 1 Merck Sharp & Dohme Corporation $869.04 04/20/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation HRRm and,or Homologous Recombination Deficiency HRD Positive Advanced Cancer No dispute reported 06/30/2026 740781393
Principal investigator 1 AstraZeneca Pharmaceuticals LP $17,025.00 04/17/2020 Non-covered Recipient Entity
University Of Florida Health Womens Health Specialists
A Phase II Study to Assess the Activity of PD-L1 Inhibition with Durvalumab after Chemo-Radiotherapy in Patients with Stage II-IV Microsatelite Stable (MSS) Rectal Cancer No dispute reported 06/30/2026 736744181
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,000.00 04/17/2020 Non-covered Recipient Entity
University Of Florida Health Womens Health Specialists
A Phase II Study of the Dual Immune Checkpoint Blockade with Durvalumab plus Tremelimumab Following Palliative Hypofractionated Radiation in Patients with Microsatellite Stable (MSS) Metastatic Colorectal Cancer Progressing on Chemotherapy No dispute reported 06/30/2026 736750051
Principal investigator 1 Incyte Corporation $2,294.10 04/09/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303783
Principal investigator 1 Incyte Corporation $1,950.00 04/09/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303785
Principal investigator 1 Incyte Corporation $3,250.00 04/02/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303769
Principal investigator 1 Incyte Corporation $1,430.00 04/02/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303771
Principal investigator 1 Incyte Corporation $119.56 04/02/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303773
Principal investigator 1 Incyte Corporation $1,578.00 04/02/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 744303781
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $56,784.00 03/25/2020 Non-covered Recipient Entity
University of Florida Board of Trustees
A Phase II, Open-label Pilot Study Evaluating theSafetyandActivityof Liposomal Irinotecan in Combination With5-FUandOxaliplatinin Preoperative Treatment ofPancreatic AdenocarcinomaNEO-Nal- IRI Study No dispute reported 06/30/2026 740100249
Principal investigator 1 AstraZeneca Pharmaceuticals LP $37,245.00 03/22/2020 Non-covered Recipient Entity
University Of Florida
CCL20 Expressions in Colorectal, Pancreatic and Biliary Duct Cancers No dispute reported 06/30/2026 736743123
Principal investigator 1 Amgen Inc. $109,364.50 03/20/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA HEALTH
AMG 510_P1/2 Monotherapy NSCLC/CRC/Tumor Agnostic_20170543 No dispute reported 06/30/2026 731622571
Principal investigator 1 AstraZeneca Pharmaceuticals LP $50.00 03/12/2020 Non-covered Recipient Entity
University Of Florida
A Phase II Study to Assess the Activity of PD-L1 Inhibition with Durvalumab after Chemo-Radiotherapy in Patients with Stage II-IV Microsatelite Stable (MSS) Rectal Cancer No dispute reported 06/30/2026 736735901
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $36,055.00 03/12/2020 Non-covered Recipient Entity
University Of Florida Board Of Trustees
A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer No dispute reported 06/30/2026 736763677
Principal investigator 1 GlaxoSmithKline, LLC. $180,018.24 03/09/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA DIVISION OF HEMATOLOGY & ONCOLOGY
214456 No dispute reported 06/30/2026 965523391
Principal investigator 1 Incyte Corporation $175.80 03/09/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303737
Principal investigator 1 Incyte Corporation $4,952.00 03/05/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 744303751
Principal investigator 1 Amgen Inc. $102,487.90 02/22/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
AMG 510_P1/2 Monotherapy NSCLC/CRC/Tumor Agnostic_20170543 No dispute reported 06/30/2026 731622579
Principal investigator 1 Incyte Corporation $19.10 02/10/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303573
Principal investigator 1 Incyte Corporation $124.14 02/10/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303575
Principal investigator 1 Incyte Corporation $47.00 02/10/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303577
Principal investigator 1 Incyte Corporation $30.40 02/10/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303579
Principal investigator 1 Incyte Corporation $377.16 02/10/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303581
Principal investigator 1 Incyte Corporation $20.34 02/10/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303583
Principal investigator 1 Incyte Corporation $45.60 02/10/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303585
Principal investigator 1 Incyte Corporation $28.65 02/10/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303587
Principal investigator 1 Incyte Corporation $35.10 02/10/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303589
Principal investigator 1 Incyte Corporation $42.36 02/10/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303591
Principal investigator 1 Incyte Corporation $47.16 02/10/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303593
Principal investigator 1 Incyte Corporation $76.00 02/10/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303595
Principal investigator 1 Incyte Corporation $100.25 02/10/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303719
Principal investigator 1 Incyte Corporation $58.50 02/10/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303721
Principal investigator 1 Incyte Corporation $117.50 02/10/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303723
Principal investigator 1 Incyte Corporation $2.08 02/10/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303725
Principal investigator 1 Incyte Corporation $165.06 02/10/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303727
Principal investigator 1 Incyte Corporation $868.98 02/10/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303729
Principal investigator 1 Incyte Corporation $193.23 02/10/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303731
Principal investigator 1 Incyte Corporation $360.06 02/10/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303733
Principal investigator 1 Incyte Corporation $18.20 02/10/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303735
Principal investigator 1 Incyte Corporation $23.40 02/10/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 744303739
Principal investigator 1 Incyte Corporation $111.12 02/10/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 744303741
Principal investigator 1 Incyte Corporation $565.74 02/10/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 744303743
Principal investigator 1 Incyte Corporation $50.85 02/10/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 744303745
Principal investigator 1 Incyte Corporation $1.32 02/10/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 744303747
Principal investigator 1 Incyte Corporation $19.10 02/10/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303753
Principal investigator 1 Incyte Corporation $19.10 02/10/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303755
Principal investigator 1 Incyte Corporation $35.10 02/10/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 744303757
Principal investigator 1 Incyte Corporation $35.10 02/10/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 744303759
Principal investigator 1 Incyte Corporation $47.16 02/10/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 744303761
Principal investigator 1 Seagen Inc. $1,534.00 02/05/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 733447599
Principal investigator 1 Seagen Inc. $3,900.00 02/05/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 733447601
Principal investigator 1 Eli Lilly and Company $15,429.00 02/04/2020 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
RANDOMIZED, DOUBLE-BLIND, PHASE 2 STUDY OF RAMUCIRUMAB OR MERESTINIB OR PLACEBO PLUS CISPLATIN AND GEMCITABINE AS FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED OR METASTATIC BILIARY TRACT CANCER No dispute reported 06/30/2026 728751429
Principal investigator 1 Incyte Corporation $9,560.00 02/04/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 744303749
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $56,784.00 02/03/2020 Non-covered Recipient Entity
University of Florida Board of Trustees
A Phase II, Open-label Pilot Study Evaluating theSafetyandActivityof Liposomal Irinotecan in Combination With5-FUandOxaliplatinin Preoperative Treatment ofPancreatic AdenocarcinomaNEO-Nal- IRI Study No dispute reported 06/30/2026 740100229
Principal investigator 1 Incyte Corporation $5,025.00 01/31/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 744303709
Principal investigator 1 Amgen Inc. $4,950.78 01/28/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA HEALTH
AMG 510_P1/2 Monotherapy NSCLC/CRC/Tumor Agnostic_20170543 No dispute reported 06/30/2026 731622567
Principal investigator 1 Amgen Inc. $38,745.29 01/27/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA HEALTH
AMG 510_P1/2 Monotherapy NSCLC/CRC/Tumor Agnostic_20170543 No dispute reported 06/30/2026 731622575
Principal investigator 1 Incyte Corporation $4,128.00 01/22/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome No dispute reported 06/30/2026 744303717
Principal investigator 1 AstraZeneca Pharmaceuticals LP $84,614.27 01/21/2020 Non-covered Recipient Entity
National Surgical Adjuvant Breast And Bowel Project Foundation, Inc
A Phase II Study to Assess the Activity of PD-L1 Inhibition with Durvalumab after Chemo-Radiotherapy in Patients with Stage II-IV Microsatelite Stable (MSS) Rectal Cancer No dispute reported 06/30/2026 736749317
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $34,396.70 01/21/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
LX1606.1-207-BTC No dispute reported 06/30/2026 752054639
Principal investigator 1 Seagen Inc. $13,457.60 01/21/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 733447605
Principal investigator 1 Merck Sharp & Dohme Corporation $37.20 01/20/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation HRRm and,or Homologous Recombination Deficiency HRD Positive Advanced Cancer No dispute reported 06/30/2026 740781275
Principal investigator 1 Merck Sharp & Dohme Corporation $210.51 01/07/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation HRRm and,or Homologous Recombination Deficiency HRD Positive Advanced Cancer No dispute reported 06/30/2026 740781311
Principal investigator 1 Merck Sharp & Dohme Corporation $462.48 01/07/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation HRRm and,or Homologous Recombination Deficiency HRD Positive Advanced Cancer No dispute reported 06/30/2026 740781313
Principal investigator 1 Merck Sharp & Dohme Corporation $21,652.48 01/07/2020 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation HRRm and,or Homologous Recombination Deficiency HRD Positive Advanced Cancer No dispute reported 06/30/2026 740781315